Guidelines for cryoprecipitate transfusion

British Columbia Medical Journal

Volumn 49, Issue 8, 2007, Pages 441-445

  Droubatchevskaia, Nadejda ^a   Wong, Michelle ^b   Chipperfield, K M ^c,d   Wadsworth, L D ^d,e,f   Ferguson, D J ^d,g  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER COASTAL HEALTH   (Canada)

^d Department of Pathology and Labaratory Medicine at UBC ^*

^e Children's and Women's Health Center of BC   (Canada)

^f Transfusion Medicine Advisory Group of BC

^g BC Biomedical Laboratories Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36949003447     PISSN: 00070556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. United States Department of Health and Human Services. Agency for Health Care Policy and Research. Acute Pain Management: Operative or Medical Procedures and Trauma. Rockville, MD: AHCPR, 1993:107. Clinical practice guideline No. 1, AHCPR publication No. 92-0023.
2. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004;126:11-28.
3. Practice guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996;84:732-747.
4. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. JAMA 1994;271:777-781.
5. Petrides M, Stack G (eds). Practical Guide to Transfusion Medicine. Bethesda, MD: AABB Press; 2001:158-160.
6. Gottschall J (ed). Blood transfusion therapy: A physician's handbook. 8th ed. Bethesda, MD: AABB Press; 2005:28, 43, 94-99.
7. Israels SJ. Factor XIII deficiency. Emedicine web site, www.emedicine.com/ ped/topic3040.htm (accessed 13 October 2006).
8. Levine MN, Goldhaber SZ, Gore JM, et al. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest 1995;108(4 suppl): 291S-301S.
9. Pantanowitz L, Kruskall MS, Uhl L. Cryoprecipitate. Patterns of use. Am J Clin Pathol 2003;119:874-881.
10. Shiono N, Koyama N, Watanabe Y et al. Application of cryoprecipitate as a hematostatic glue. J Cardiovasc Surg (Torino) 1998;39:609-612.
11. Milne AA, Murphy WG, Reading SJ, et al. A randomised trial of fibrin sealant in peripheral vascular surgery. Vox Sang 1996;70:210-212.
12. Streiff MB, Ness PM. Acquired FV inhibitors: A needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002;42:18-26.
13. Poon MC. Cryoprecipitate: Uses and alternatives. Transfus Med Rev 1993;7: 180-192.
14. Hesselvik F, Brodin B, Carlsson C, et al. Cryoprecipitate infusion fails to improve organ function in septic shock. Crit Care Med 1987;15:475-483.